Compare Amphastar Pharmaceuticals Inc (AMPH) vs Howmet Aerospace Inc (HWM) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

Howmet Aerospace (HWM) trades at $270.85, down 1.07% on the day, with a bullish technical outlook supported by moving averages and key support at $268. The company reported strong profitability with a 20.22% net margin and ROE of 33.98%, though Q1 2026 earnings missed expectations. Recent news highlights growth in commercial aerospace and defense sectors, with Q2 2026 results due August 6, 2026.

HWM's premium valuation (P/E 62.84) reflects growth optimism, but execution risks and earnings volatility pose challenges. Analyst consensus is bullish with a $317.29 price target, suggesting 17% upside. Investors should weigh robust cash flow and sector tailwinds against high multiples and macroeconomic sensitivity.